捆绑白丝jk震动捧娇喘视频_国产一级不卡黄色av_久爱视频2019午夜视频_2020国产特级黄色自拍_亚洲熟妇AV日韩熟妇AV_国产精品欧美天美传媒_水蜜桃亚洲成人无码_歐美在線視頻網_日韩在线成人毛片_人妻激情中文字幕

 

 

 

Data shows that in the first half of 2024, 19 of the top 20 products of diabetes chemical drugs (including biological drugs) at retail pharmacies in China will have sales of more than 100 million yuan. The sales revenue of Simeglutide Injection exceeded 1 billion yuan, a year-on-year increase of 142.84%.

 

 

 

According to the data, Simeglutide Injection was developed by Novo Nordisk and was approved to enter the Chinese market in 2021. It is reported that there are also multiple domestic pharmaceutical companies competing to lay out Simeglutide Injection, such as Hangzhou Jiuyuan Gene, Lizhu Group New Beijiang Pharmaceutical, and Qilu Pharmaceutical, which have reported for production and are currently under review. However, East China Pharmaceutical said in its third quarterly report that all subjects in the Phase III clinical study on the indications of Smeglutide injection for diabetes had been enrolled. It is expected that the main endpoint data will be obtained in the fourth quarter of 2024 and submitted to pre BLA for communication. In addition, the clinical application for semaglutide injection from Zhejiang Prokangyu Pharmaceutical has also been accepted by CDE.

 

 

 

The sales revenue of Dapagliflozin tablets exceeds 800 million yuan, and there are currently 4 companies selling them. Data shows that daggligin tablet is a new type of oral hypoglycemic drug of SGLT-2 inhibitor (sodium glucose cotransporter 2) for the treatment of type 2 diabetes. Dapagliflozin is a new oral hypoglycemic drug developed by Bristol Myers Squibb (transferred to AstraZeneca). It was approved for market launch in Europe in November 2012, and the original product was approved for entry into the Chinese market in March 2017. It is reported that in September this year, Qilu Pharmaceutical's Dapagliflozin tablets were approved for production as imitations of Class 4.

 

 

 

The sales revenue of metformin hydrochloride tablets exceeds 500 million yuan, and there are currently 57 companies selling them. Data shows that the main component of metformin hydrochloride tablets is metformin hydrochloride, which can reduce hepatic glucose production and inhibit intestinal absorption of glucose. It can also increase the uptake and utilization of glucose by peripheral tissues, and improve insulin sensitivity. It is mainly applicable to type 2 diabetes patients who are ineffective in simple diet control and physical exercise treatment, especially obese type 2 diabetes patients.

 

 

 

In addition, according to the analysis, the sales revenue of metformin hydrochloride sustained-release tablets and acarbose tablets exceeds 300 million yuan, with 45 and 15 companies currently on sale respectively. The sales revenue of insulin glargine injection exceeds 200 million yuan, with 5 companies on sale. Thirteen products, including sitagliptin phosphate tablets, aspart insulin 30 injection, and glimepiride tablets, have sales exceeding 100 million yuan.

 

 

 

From the perspective of treatment categories, there are a large number of insulin and similar drugs, with 5 of them. Degu Mendong Double Insulin Injection is a newly listed product; There is fierce competition between two metformin hydrochloride products, metformin hydrochloride tablets and metformin hydrochloride sustained-release tablets, with 57 and 45 companies selling them respectively.

 

 

 

In recent years, driven by a variety of factors, China's diabetes drug market demand has continued to grow, while pharmaceutical enterprises have also continued to increase the size of this field. It is reported that recently, new products of diabetes drugs have been reported frequently, such as Henson Pharmaceutical's Engelgin Tablets, Hunan Huize Biological Medicine's Metformin Engelgin Tablets (V) and Metformin Engelgin Tablets (VI) have been approved. Since this year, 34 products (120 product specifications) of diabetes drugs have been approved for marketing.